QTNT Quotient Ltd.
Quotient Ltd. is a commercial-stage diagnostics company. It provides immunohematology products to hospitals and blood banks. The company develops, manufactures and sells conventional reagent products to equipment manufacturers. It engages in transfusion diagnostics, which focuses on blood grouping and serological disease screening. Quotient was founded on January 28, 2012 and is headquartered in Eysins, Switzerland.
Company profile
Ticker
QTNT
Exchange
Website
CEO
Franz Walt
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
Investment data
Securities sold
Number of investors
Calendar
4 Feb 20
5 Jun 20
31 Mar 21
News
Company financial data Financial data
| Quarter (USD) | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | 7.94M | 7.85M | 8.17M | 8.28M | |
| Net income | -27.49M | -26.99M | -23.57M | -26.59M | |
| Diluted EPS | -0.37 | -0.41 | -0.36 | -0.39 | |
| Net profit margin | -346% | -344% | -289% | -321% | |
| Operating income | -22.36M | -18.44M | -18.42M | -20.33M | |
| Net change in cash | -1.15M | -712K | 2.43M | -372K | |
| Cash on hand | 4.66M | 5.82M | 6.53M | 4.1M | |
| Cost of revenue | 4.53M | 3.97M | 4.56M | 4.43M |
| Annual (USD) | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|
| Revenue | 29.13M | 24.73M | 22.23M | 18.52M | |
| Net income | -105.39M | -82.34M | -85.07M | -33.88M | |
| Diluted EPS | -1.92 | -2.02 | -3.02 | -1.73 | |
| Net profit margin | -362% | -333% | -383% | -183% | |
| Operating income | -78.96M | -69.99M | -74.06M | -49.09M | |
| Net change in cash | -16.07M | 15.41M | -39.35M | 6.58M | |
| Cash on hand | 4.1M | 20.17M | 4.75M | 44.1M | |
| Cost of revenue | 17.23M | 10.47M | 10.84M | 9.66M |
Financial data from Quotient earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|
| 28 May 20 | Stackawitz Jeremy | Ordinary Shares | Sell | Dispose S | 7.41 | 11,000 | 81.51K | 142,926 |
| 28 May 20 | Farrell Edward | Ordinary Shares | Sell | Dispose S | 7.4 | 12,811 | 94.8K | 29,013 |
| 24 May 20 | Farrell Edward | Ordinary Shares | Option exercise | Aquire M | 0 | 27,258 | 0 | 41,824 |
| 24 May 20 | Farrell Edward | RSU Ordinary Shares | Grant | Aquire A | 0 | 55,000 | 0 | 55,000 |
| 24 May 20 | Farrell Edward | RSU Ordinary Shares | Option exercise | Dispose M | 0 | 15,000 | 0 | 30,000 |
| 24 May 20 | Farrell Edward | RSU Ordinary Shares | Option exercise | Dispose M | 0 | 12,258 | 0 | 12,257 |
| 24 May 20 | Buhler Peter | RSU Ordinary Shares | Grant | Aquire A | 0 | 55,000 | 0 | 55,000 |
| 24 May 20 | Lindop Christopher J | Ordinary Shares | Option exercise | Aquire M | 0 | 25,271 | 0 | 376,647 |
| 24 May 20 | Lindop Christopher J | RSU Ordinary Shares | Option exercise | Dispose M | 0 | 15,000 | 0 | 30,000 |
| 24 May 20 | Lindop Christopher J | RSU Ordinary Shares | Option exercise | Dispose M | 0 | 10,271 | 0 | 10,270 |
Institutional ownership Q1 2020
74.0% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 85 |
| Opened positions | 16 |
| Closed positions | 15 |
| Increased positions | 30 |
| Reduced positions | 22 |
13F shares |
Current |
|---|---|
| Total value | 235.35M |
| Total shares | 59.44M |
| Total puts | 32.5K |
| Total calls | 57.6K |
| Total put/call ratio | 0.6 |
Largest owners |
Shares | Value |
|---|---|---|
| Perceptive Advisors | 13.29M | $52.49M |
| POLR Polar Capital | 7.61M | $30.06M |
| AMP Ameriprise Financial | 4.2M | $16.61M |
| Highbridge Capital Management | 4.16M | $16.45M |
| Cormorant Asset Management | 3.16M | $12.49M |
| Clearbridge Advisors | 3.05M | $12.06M |
| TimesSquare Capital Management | 2.92M | $11.55M |
| MS Morgan Stanley | 2.82M | $11.13M |
| CS Credit Suisse | 2.73M | $10.79M |
| Farallon Capital Management | 2.5M | $9.88M |
Financial report summary
?Risks
- Our commercialization plan for MosaiQ in the patient testing market may depend on entering into arrangements with one or more commercial partners.
Management Discussion
- Total revenue and product sales for the quarter ended December 31, 2019 increased by 18% to $7.9 million, compared with $6.7 million for the quarter ended December 31, 2018. The increase in total revenue was due to $0.3 million of other revenues arising from the achievement of product development milestones in the quarter ended December 31, 2019 and an increase of 14% in product sales. The increase in product sales was primarily attributable to growth in product sales to OEM customers and incremental direct sales of conventional reagent products to customers in the United States. Products sold by standing purchase order were 72% of product sales for the quarter ended December 31, 2019, compared with 67% for the quarter ended December 31, 2018.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
appointed, attempt, Boyd, Buhler, choose, deal, declaration, defend, dispute, Ernest, FidFund, fragmented, framework, infrastructure, inherent, Larnach, member, merit, overlap, Peter, proceeding, put, resign, resolution, resolving, restructuring, Roland, SA, SE, seeking, serve, social, stage, strained, Suisse, threatened, Vice, vigorously, wider
Removed:
consecutive, decreased, generated, partially, reduced, Rule
Financial reports
10-Q
2020 Q3
Quarterly report
4 Feb 20
10-Q
2020 Q2
Quarterly report
4 Nov 19
10-Q
2020 Q1
Quarterly report
6 Aug 19
10-K/A
2019 FY
Annual report (amended)
14 Jun 19
10-K
2019 FY
Annual report
29 May 19
10-Q
2019 Q3
Quarterly report
5 Feb 19
10-Q
2019 Q2
Quarterly report
6 Nov 18
10-Q
2019 Q1
Quarterly report
7 Aug 18
10-K
2018 FY
Annual report
30 May 18
10-Q
2017 Q3
Quarterly report
6 Feb 18
Current reports
8-K
Quotient Limited and hVIVO Announce Partnership to Support Wide-SpreadCOVID-19 Antibody Testing in the UK
11 May 20
8-K
Quotient Limited Provides an Update on Recent MosaiQ Milestone Achievements together with Third Quarter Fiscal 2020 Results
30 Jan 20
8-K
Departure of Directors or Certain Officers
7 Jan 20
8-K
Entry into a Material Definitive Agreement
27 Dec 19
8-K
Entry into a Material Definitive Agreement
13 Dec 19
8-K
Termination of a Material Definitive Agreement
27 Nov 19
8-K
Termination of a Material Definitive Agreement
13 Nov 19
8-K
Entry into a Material Definitive Agreement
12 Nov 19
8-K
Other Events
6 Nov 19
8-K
Positive results from the initial Serological Disease Screening microarray US field trial
4 Nov 19
Registration and prospectus
S-8
Registration of securities for employees
6 Feb 20
424B3
Prospectus supplement
20 Dec 19
S-3
Shelf registration
13 Dec 19
424B5
Prospectus supplement for primary offering
7 Nov 19
424B5
Prospectus supplement for primary offering
6 Nov 19
S-8
Registration of securities for employees
7 Jun 19
424B5
Prospectus supplement for primary offering
31 May 19
424B5
Prospectus supplement for primary offering
7 Dec 18
424B5
Prospectus supplement for primary offering
6 Dec 18
S-8
Registration of securities for employees
9 Nov 18
Proxies
Other
CT ORDER
Confidential treatment order
6 Mar 20
CT ORDER
Confidential treatment order
6 Mar 20
EFFECT
Notice of effectiveness
23 Dec 19
CT ORDER
Confidential treatment order
1 Mar 19
EFFECT
Notice of effectiveness
24 Aug 18
CORRESP
Correspondence with SEC
22 Aug 18
UPLOAD
Letter from SEC
21 Aug 18
EFFECT
Notice of effectiveness
21 Nov 17
CORRESP
Correspondence with SEC
20 Nov 17
UPLOAD
Letter from SEC
17 Nov 17
Ownership
4
Quotient / Jeremy Stackawitz ownership change
1 Jun 20
4
Quotient / Edward Farrell ownership change
1 Jun 20
4
Quotient / CHRISTOPHER J LINDOP ownership change
26 May 20
4
Quotient / Ernest Larnach ownership change
26 May 20
4
Quotient / Franz Walt ownership change
26 May 20
4
Quotient / Jeremy Stackawitz ownership change
26 May 20
4
Quotient / Edward Farrell ownership change
26 May 20
4
Quotient / Peter Buhler ownership change
26 May 20
4
Quotient / L JOHN WILKERSON ownership change
4 May 20
4
Quotient / Brian McDonough ownership change
4 May 20